10092 Federal Register / Vol. 86, No. 31 / Thursday, February 18, 2021 / Notices 

I. Purpose 

In accordance with section 10(a) of 

the Federal Advisory Committee Act, 5 

U.S.C. App., this notice announces a 

meeting of the National Advisory 

Council for Healthcare Research and 

Quality (the Council). The Council is 

authorized by Section 941 of the Public 

Health Service Act, 42 U.S.C. 299c. In 

accordance with its statutory mandate, 

the Council is to advise the Secretary of 

the Department of Health and Human 

Services and the Director of AHRQ on 

matters related to AHRQ’s conduct of its 

mission including providing guidance 

on (A) priorities for health care research, 

(B) the field of health care research 

including training needs and 

information dissemination on health 

care quality and (C) the role of the 

Agency in light of private sector activity 

and opportunities for public private 

partnerships. The Council is composed 

of members of the public, appointed by 

the Secretary, and Federal ex-officio 

members specified in the authorizing 

legislation. 

II. Agenda 

On Thursday, March 18, 2021, the 

Council meeting will convene at 10:00 

a.m., with the call to order by the 

Council Chair and approval of previous 

Council summary notes. The meeting 

will begin with an update on AHRQ’s 

recent accomplishments in Health 

Systems Research, Practice 

Improvement, Data and Analytics, and 

achieving organizational excellence. 

The agenda will also include a 

discussion of communication and value 

of health systems research, an update on 

PCOR Trust Funds, and a discussion of 

how AHRQ may advance health equity. 

The meeting will adjourn at 2:00 p.m. 

The meeting is open to the public. For 

information regarding how to access the 

meeting as well as other meeting details, 

including information on how to make 

a public comment, please go to https:// 

www.ahrq.gov/news/events/nac/. The 

final agenda will be available on the 

AHRQ website no later than Thursday, 

March 11, 2021. 

Dated: February 11, 2021. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2021–03182 Filed 2–17–21; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP)—Funding 

Opportunity Announcement (FOA), 

PAR 20–280, Cooperative Research 

Agreements to the World Trade Center 

Health Program (U01); and RFA OH– 

21–004, Exploratory/Developmental 

Grants Related to the World Trade 

Center Health Program (R21); 

Amended Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Disease, Disability, 

and Injury Prevention and Control 

Special Emphasis Panel (SEP)—Funding 

Opportunity Announcement (FOA), 

PAR 20–280, Cooperative Research 

Agreements to the World Trade Center 

Health Program (U01); and RFA OH–21– 

004, Exploratory/Developmental Grants 

Related to the World Trade Center 

Health Program (R21), March 16–17, 

2021, from 9:00 a.m.–6:00 p.m., EDT; 

and March 18, 2021, from 9:00 a.m.– 

12:00 p.m., EDT, in the original FRN. 

The virtual meeting was published in 

the Federal Register on Monday, 

January 11, 2021, Volume 86, Number 6, 

pages 1975–1976. 

The virtual meeting is being amended 

to change the dates and times and 

should read as follows: 

Dates and Times: March 16–17, 2021, 

from 1:00 p.m.–5:00 p.m., EDT. 

The meeting is closed to the public. 

FOR FURTHER INFORMATION CONTACT: 

Marilyn Ridenour B.S.N., M.B.A., 

M.P.H., C.P.H., C.I.C., CAPT, USPHS, 

Scientific Review Officer, CDC, National 

Institute for Occupational Safety and 

Health, 1095 Willowdale Road, Mailstop 

1811, Morgantown, West Virginia 

26505, Telephone (304) 285–5879. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–03230 Filed 2–17–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA 

R13 Conference Grant Review. 

Date: April 1, 2021. 

Time: 11:00 a.m. to 12:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Preethy Nayar, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, National Institute on Drug Abuse, 

NIH, 301 North Stonestreet Avenue, MSC 

6021 Bethesda, MD 20892, 301–443–4577 

nayarp2@csr.nih.gov 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: February 11, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–03187 Filed 2–17–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Allogeneic Therapy for 

the Treatment of Autoimmune Disease 

Using Chimeric Antigen Receptors 

Targeting CD19 

AGENCY: National Institutes of Health, 

HHS. 


jbell on DSKJLSW7X2PROD with NOTICES